ARCHIVES

Patenting the Gene: Cancer Advocates and Industry Diverge on Myriad Ruling

This article is from The Cancer Letter archive.

Vol. 39 No. 24 | June 14, 2013

Download PDF Visit The Full Archive

Related Articles

Bristol-Myers, IVAX submit Competing Application for Paclitaxel Use In KS

April 18, 1997

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

October 1, 1976

Hopkins, Pennsylvania Ok’d As Comprehensive; No. Remains At 24

May 24, 1991

In Brief: Voters Support Increase In Research Funds, Poll Finds; Baynes Heads BMT Unit In Detroit

February 28, 1997

NSABP Submits Appeal To NIH To Reverse Cancellation Of P-4 Chemoprevention Trial.

August 10, 2007

Detroit Center Formally Recognized As Comprehensive

August 4, 1978